Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 11/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932110 | 0.92 | ACKR3 (0.41) | PTGESACKR3L3MBTL1USP30SSTR1 | |
| SCHEMBL11932108 | 0.89 | PTGES (0.49) | PTGESACKR3USP30MEN1LMNA | |
| SCHEMBL10006303 | 0.88 | PTGES (0.46) | PTGESACKR3MEN1LMNAKMT2A | |
| SCHEMBL11932111 | 0.86 | SLC6A3 (0.46) | PTGESACKR3USP30MEN1LMNA | |
| SCHEMBL10006355 | 0.83 | HTR1E (0.50) | PTGESACKR3USP30SSTR1SSTR4 | |
| SCHEMBL10006323 | 0.82 | HTR1E (0.43) | PTGESACKR3USP30MEN1LMNA | |
| SCHEMBL11932102 | 0.82 | HTR1E (0.43) | PTGESACKR3USP30SSTR1SSTR4 | |
| SCHEMBL11932103 | 0.82 | HTR1E (0.43) | PTGESACKR3USP30MEN1LMNA | |
| SCHEMBL1178777 | 0.81 | PTGES (0.42) | PTGESACKR3MEN1ALDH1A1LMNA | |
| SCHEMBL11932107 | 0.81 | HTR1E (0.42) | PTGESACKR3MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649045-B1 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | PTGES 1094/4885ACKR3 3131/4885L3MBTL1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.